TOSYMRA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tosymra, and what generic alternatives are available?
Tosymra is a drug marketed by Upsher Smith Labs and is included in one NDA. There are seven patents protecting this drug.
This drug has seventy patent family members in twenty-one countries.
The generic ingredient in TOSYMRA is sumatriptan. There are twenty-four drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the sumatriptan profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tosymra
A generic version of TOSYMRA was approved as sumatriptan by LANNETT CO INC on February 19th, 2016.
Summary for TOSYMRA
International Patents: | 70 |
US Patents: | 7 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for TOSYMRA |
What excipients (inactive ingredients) are in TOSYMRA? | TOSYMRA excipients list |
DailyMed Link: | TOSYMRA at DailyMed |


Pharmacology for TOSYMRA
Drug Class | Serotonin-1b and Serotonin-1d Receptor Agonist |
Mechanism of Action | Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for TOSYMRA
US Patents and Regulatory Information for TOSYMRA
TOSYMRA is protected by seven US patents.
Patents protecting TOSYMRA
Formulations comprising triptan compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE
Alkylglycoside compositions for drug administration
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Compositions for drug administration
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE
Formulations comprising triptan compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE
Compositions for drug administration
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Formulations comprising triptan compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE
Formulations comprising triptan compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Upsher Smith Labs | TOSYMRA | sumatriptan | SPRAY;NASAL | 210884-001 | Jan 25, 2019 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Upsher Smith Labs | TOSYMRA | sumatriptan | SPRAY;NASAL | 210884-001 | Jan 25, 2019 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Upsher Smith Labs | TOSYMRA | sumatriptan | SPRAY;NASAL | 210884-001 | Jan 25, 2019 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Upsher Smith Labs | TOSYMRA | sumatriptan | SPRAY;NASAL | 210884-001 | Jan 25, 2019 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Upsher Smith Labs | TOSYMRA | sumatriptan | SPRAY;NASAL | 210884-001 | Jan 25, 2019 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TOSYMRA
See the table below for patents covering TOSYMRA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2012513412 | See Plans and Pricing | |
European Patent Office | 3678649 | FORMULATIONS D'ÉPINÉPHRINE INTRANASALE ET MÉTHODES DE TRAITEMENT D'UNE MALADIE (INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE) | See Plans and Pricing |
World Intellectual Property Organization (WIPO) | 2011036521 | See Plans and Pricing | |
European Patent Office | 2480197 | FORMULATIONS COMPRENANT DES COMPOSÉS TRIPTAN (FORMULATIONS COMPRISING TRIPTAN COMPOUNDS) | See Plans and Pricing |
United Kingdom | 2587934 | Intranasal epinephrine formulations and methods for the treatment of disease | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |